Journal of Clinical Medicine and Research

Volume 4 Number 8 November 2012 ISSN 2141-2235



ABOUT JCMR

The Journal of Clinical Medicine and Research (JCMR) is published monthly (one volume per year) by Academic Journals.

Journal of Clinical Medicine and Research (JCMR) is an open access journal that provides rapid publication (monthly) of articles in all areas of the subject such as cardiology, critical care medicine, Family Medicine, geriatrics, pediatrics etc.

The Journal welcomes the submission of manuscripts that meet the general criteria of significance and scientific excellence. Papers will be published shortly after acceptance. All articles published in JCMR are peer-reviewed.

Submission of Manuscript

Submit manuscripts as e-mail attachment to the Editorial Office at: jcmr@academicjournals.org. A manuscript number will be mailed to the corresponding author shortly after submission.

For all other correspondence that cannot be sent by e-mail, please contact the editorial office (at jcmr@academicjournals.org).

The Journal of Clinical Medicine and Research will only accept manuscripts submitted as e-mail attachments.

Please read the **Instructions for Authors** before submitting your manuscript. The manuscript files should be given the last name of the first author.

Editors

Prof. Neveen Helmy Ahmed Aboelsoud,

Complementary Medicine Researches & Applications (CAM),
National Research Center,
Research St (Tahrir),
Dokki ,Cairo,
Egypt.

Prof. Bodh Raj Panhotra,

Department of Medical Microbiology, Medical Laboratory Technology & Clinical Sciences, Sardar Bhagwan Singh Postgraduate Institute of Biomedical Sciences & Research, Balawala, Dehradun, India.

Editorial Board

Prof. Ahmed BaHammam,

King Saud University, Saudi Arabia.

Dr. Ellen Rosskam,

Senior Scholar, Woodrow Wilson International Center for Scholars,

Washington, D.C.,

Adjunct Professor, University of Massachusetts, Lowell, Visiting Senior Fellow, University of Surrey, Faculty of Health and Medical Sciences, England, Switzerland.

Dr. Philippe Connes,

National Institute of Health and Medical Research (763), Academic Hospital of Pointe a Pitre, Guadelooupe (French West Indies), Guadeloupe.

Dr. Robert G Bota,

University of Missouri, Kansas City, USA.

Dr. Haiyang Zhou,

Department of General Surgery, Changzheng Hospital, Second Military Medical University. China.

Dr. Jimmy Jose,

SAC College of Pharmacy, Karnataka, India.

Dr. Carlos A. Feldstein,

Hospital de Clinicas Jose de San Martin, Av. Cordoba 2351 Buenos Aires 1120, Argentina.

Dr. Fadia Mostafa Attia,

Faculty of Medicine, Suez Canal University, Egypt.

Dr. Hamza Mujagic,

Massachusetts General Hospital, USA.

Dr. O.U.J. Umeora,

Ebonyi State University/Teaching Hospital, Nigeria.

Instructions for Author

Electronic submission of manuscripts is strongly encouraged, provided that the text, tables, and figures are included in a single Microsoft Word file (preferably in Arial font).

The **cover letter** should include the corresponding author's full address and telephone/fax numbers and should be in an e-mail message sent to the Editor, with the file, whose name should begin with the first author's surname, as an attachment.

Article Types

Three types of manuscripts may be submitted:

Regular articles: These should describe new and carefully confirmed findings, and experimental procedures should be given in sufficient detail for others to verify the work. The length of a full paper should be the minimum required to describe and interpret the work clearly.

Short Communications: A Short Communication is suitable for recording the results of complete small investigations or giving details of new models or hypotheses, innovative methods, techniques or apparatus. The style of main sections need not conform to that of full-length papers. Short communications are 2 to 4 printed pages (about 6 to 12 manuscript pages) in length.

Reviews: Submissions of reviews and perspectives covering topics of current interest are welcome and encouraged. Reviews should be concise and no longer than 4-6 printed pages (about 12 to 18 manuscript pages). Reviews are also peer-reviewed.

Review Process

All manuscripts are reviewed by an editor and members of the Editorial Board or qualified outside reviewers. Authors cannot nominate reviewers. Only reviewers randomly selected from our database with specialization in the subject area will be contacted to evaluate the manuscripts. The process will be blind review.

Decisions will be made as rapidly as possible, and the journal strives to return reviewers' comments to authors as fast as possible. The editorial board will re-review manuscripts that are accepted pending revision. It is the goal of the JCMR to publish manuscripts within weeks after submission.

Regular articles

All portions of the manuscript must be typed **double-spaced** and all pages numbered starting from the title page.

The **Title** should be a brief phrase describing the contents of the paper. The Title Page should include the authors' full names and affiliations, the name of the corresponding author along with phone, fax and E-mail information. Present addresses of authors should appear as a footnote.

The **Abstract** should be informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The Abstract should be 100 to 200 words in length.. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Standard nomenclature should be used and abbreviations should be avoided. No literature should be cited.

Following the abstract, about 3 to 10 **key words** that will provide indexing references should be listed.

A list of non-standard **Abbreviations** should be added. In general, non-standard abbreviations should be used only when the full term is very long and used often. Each abbreviation should be spelled out and introduced in parentheses the first time it is used in the text. Only recommended SI units should be used. Authors should use the solidus presentation (mg/ml). Standard abbreviations (such as ATP and DNA) need not be defined.

The **Introduction** should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines.

Materials and methods should be complete enough to allow experiments to be reproduced. However, only truly new procedures should be described in detail; previously published procedures should be cited, and important modifications of published procedures should be mentioned briefly. Capitalize trade names and include the manufacturer's name and address. Subheadings should be used. Methods in general use need not be described in detail.

Results should be presented with clarity and precision. The results should be written in the past tense when describing findings in the authors' experiments. Previously published findings should be written in the present tense. Results should be explained, but largely without referring to the literature. Discussion, speculation and detailed interpretation of data should not be included in the Results but should be put into the Discussion section.

The **Discussion** should interpret the findings in view of the results obtained in this and in past studies on this topic. State the conclusions in a few sentences at the end of the paper. The Results and Discussion sections can include subheadings, and when appropriate, both sections can be combined.

The **Acknowledgments** of people, grants, funds, etc should be brief.

Tables should be kept to a minimum and be designed to be as simple as possible. Tables are to be typed double-spaced throughout, including headings and footnotes. Each table should be on a separate page, numbered consecutively in Arabic numerals and supplied with a heading and a legend. Tables should be self-explanatory without reference to the text. The details of the methods used in the experiments should preferably be described in the legend instead of

in the text. The same data should not be presented in both table and graph form or repeated in the text.

Figure legends should be typed in numerical order on a separate sheet. Graphics should be prepared using applications capable of generating high resolution GIF, TIFF, JPEG or Powerpoint before pasting in the Microsoft Word manuscript file. Tables should be prepared in Microsoft Word. Use Arabic numerals to designate figures and upper case letters for their parts (Figure 1). Begin each legend with a title and include sufficient description so that the figure is understandable without reading the text of the manuscript. Information given in legends should not be repeated in the text.

References: In the text, a reference identified by means of an author's name should be followed by the date of the reference in parentheses. When there are more than two authors, only the first author's name should be mentioned, followed by 'et al'. In the event that an author cited has had two or more works published during the same year, the reference, both in the text and in the reference list, should be identified by a lower case letter like 'a' and 'b' after the date to distinguish the works.

Examples:

Nishimura (2000), Agindotan et al. (2003), (Kelebeni, 1983), (Usman and Smith, 2001), (Chege, 1998; Stein, 1987a,b; Tijani, 1993,1995), (Kumasi et al., 2001)

References should be listed at the end of the paper in alphabetical order. Articles in preparation or articles submitted for publication, unpublished observations, personal communications, etc. should not be included in the reference list but should only be mentioned in the article text (e.g., A. Kingori, University of Nairobi, Kenya, personal communication). Journal names are abbreviated according to Chemical Abstracts. Authors are fully responsible for the accuracy of the references.

Examples:

Giesielski SD, Seed TR, Ortiz JC, Melts J (2001). Intestinal parasites among North Carolina migrant farm workers. Am. J. Public Health. 82: 1258-1262

Stoy N, Mackay GM, Forrest CM, Christofides J, Egerton M, Stone TW, Darlington LG (2005). Tryptophan metabolism and oxidative stress in patients with Huntington's disease. N. J. Neurochem. 93: 611–623.

Mussel RL, De Sa Silva E, Costa AM, Mandarim-De-Lacerda CA (2003). Mast cells in tissue response to dentistry materials: an adhesive resin, a calcium hydroxide and a glass ionomer cement. J. Cell. Mol. Med. 7:171-178.

Booth M, Bundy DA, Albonico P, Chwaya M, Alawi K (1998). Associations among multiple geohelminth infections in school children from Pemba Island. Parasitol. 116: 85-93.0.

Fransiscus RG, Long JC, (1991). Variation in human nasal height and breath, Am. J. Phys. Anthropol. 85(4):419-427.

Stanislawski L, Lefeuvre M, Bourd K, Soheili-Majd E, Goldberg M, Perianin A (2003). TEGDMA-induced toxicity in human fibroblasts is associated with early and drastic glutathione depletion with subsequent production of oxygen reactive species. J. Biomed. Res. 66:476-82.

Case Studies

Case Studies include original case reports that will deepen the understanding of general medical knowledge

The **Title** should be a brief phrase describing the contents of the paper. The Title Page should include the authors' full names and affiliations, the name of the corresponding author along with phone, fax and E-mail information. Present addresses of authors should appear as a footnote.

The Abstract should be informative and completely self-explanatory, briefly present the topic, state the scope of the experiments, indicate significant data, and point out major findings and conclusions. The Abstract should be 100 to 200 words in length. Complete sentences, active verbs, and the third person should be used, and the abstract should be written in the past tense. Standard nomenclature should be used and abbreviations should be avoided. No literature should be cited.

Following the abstract, about 3 to 10 **key words** that will provide indexing references should be listed.

A list of non-standard **Abbreviations** should be added. In general, non-standard abbreviations should be used only when the full term is very long and used often. Each abbreviation should be spelled out and introduced in parentheses the first time it is used in the text. Only recommended SI units should be used. Authors should use the solidus presentation (mg/ml).

The **Introduction** should provide a clear statement of the problem, the relevant literature on the subject, and the proposed approach or solution. It should be understandable to colleagues from a broad range of scientific disciplines. The presentation of the case study should include the important information regarding the case. This must include the medical history, demographics, symptoms, tests etc. Kindly note that all information that will lead to the identification of the particular patient(s) must be excluded.

The conclusion should highlight the contribution of the study and its relevance in general medical knowledge

The **Acknowledgments** of people, grants, funds, etc should be brief.

References: Same as in regular articles

Short Communications

Short Communications are limited to a maximum of two figures and one table. They should present a complete study that is more limited in scope than is found in full-length papers. The items of manuscript preparation listed above apply to Short Communications with the following differences: (1) Abstracts are limited to 100 words; (2) instead of a separate Materials and Methods section, experimental procedures may be incorporated into Figure Legends and Table footnotes; (3) Results and Discussion should be combined into a single section.

Proofs and Reprints: Electronic proofs will be sent (e-mail attachment) to the corresponding author as a PDF file. Page proofs are considered to be the final version of the manuscript. With the exception of typographical or minor clerical errors, no changes will be made in the manuscript at the proof stage. Because IJMMS will be published freely online to attract a wide audience), authors will have free electronic access to the full text (in both HTML and PDF) of the article. Authors can freely download the PDF file from which they can print unlimited copies of their articles.

Fees and Charges: Authors are required to pay a \$550 handling fee. Publication of an article in the Journal of Clinical Medicine and Research is not contingent upon the author's ability to pay the charges. Neither is acceptance to pay the handling fee a guarantee that the paper will be accepted for publication. Authors may still request (in advance) that the editorial office waive some of the handling fee under special circumstances.

Copyright: © 2012, Academic Journals.

All rights Reserved. In accessing this journal, you agree that you will access the contents for your own personal use but not for any commercial use. Any use and or copies of this Journal in whole or in part must include the customary bibliographic citation, including author attribution, date and article title.

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, or thesis) that it is not under consideration for publication elsewhere; that if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher.

Disclaimer of Warranties

In no event shall Academic Journals be liable for any special, incidental, indirect, or consequential damages of any kind arising out of or in connection with the use of the articles or other material derived from the JCMR, whether or not advised of the possibility of damage, and on any theory of liability.

This publication is provided "as is" without warranty of any kind, either expressed or implied, including, but not limited to, the implied warranties of merchantability, fitness for a particular purpose, or non-infringement. Descriptions of, or references to, products or publications does not imply endorsement of that product or publication.

While every effort is made by Academic Journals to see that no inaccurate or misleading data, opinion or statements appear in this publication, they wish to make it clear that the data and opinions appearing in the articles and advertisements herein are the responsibility of the contributor or advertiser concerned. Academic Journals makes no warranty of any kind, either express or implied, regarding the quality, accuracy, availability, or validity of the data or information in this publication or of any other publication to which it may be linked.

Journal of Clinical Medicine and Research

Table of Content:Volume 4Number 8November 2012

ARTICLES

Research Articles

Relationship between blood pressure and arterial stiffness in patients undergoing antihypertensive treatment: A pilot study
Anumeha Bhagat, Nandini Kapoor and Jeet Ram Kashyap

94

Investigation of influence of inside out transobturator vaginal tape (TVT-O) procedure on objective, subjective cure rates and different quality of life tests in stress urinary incontinence treatment

100

Murat BOZKURT and A. Ender YUMRU

Full Length Research Paper

Relationship between blood pressure and arterial stiffness in patients undergoing antihypertensive treatment: A pilot study

Anumeha Bhagat^{1*}, Nandini Kapoor¹ and Jeet Ram Kashyap²

¹Department of Physiology, Government Medical College and Hospital, Chandigarh, India. ²Department of Cardiology, All India Institute of Medical Sciences (AIIMS), New Delhi, India.

Accepted 21 August, 2012

Mean arterial blood pressure is one of the principal modifiable factors which contribute to arterial The influence of anti hypertensive drugs on arterial stiffness measured photoplethysmographically has not yet been studied. This pilot study was aimed at exploring the relationship between blood pressure (BP) and parameters of arterial stiffness on initiating antihypertensive treatment. Fourteen newly diagnosed hypertensive male or female patients aged 30 to 40 years participated in the study. The age, height, weight and body mass index was calculated for all patients. BP and arterial stiffness were measured once before treatment and weakly after initiation of treatment for 3 weeks. On comparing the pretreatment and post treatment weakly BP values, a highly significant decline in the systolic BP (p< 0.006) and mean BP (0.005) was observed, whereas diastolic BP showed a significant (0.016) decline. Post hoc analysis revealed that systolic BP (SBP) and diastolic BP (DBP) showed a significant decline (p = 0.011 and 0.027, respectively) at the second visit, which was around two weeks post treatment, while the mean BP showed a highly significant decrease (p = 0.009) at this time. However, pulse pressure and heart rate did not change significantly with treatment. Also, the parameters of arterial stiffness did not change significantly with treatment for the same duration. Thus, we concluded that reduction in BP in hypertensive patients as measured clinically by brachial cuff sphygmanometry seems to be dependent on the encounter interval. The decrease in blood pressure occured within three weeks, whereas changes in arterial stiffness do not occur even till three weeks of initiating the treatment.

Key words: Antihypertensive treatment, photoplethysmographic arterial stiffness, encounter interval.

INTRODUCTION

Increased arterial stiffness is a marker of cardiovascular damage, even in the absence of clinically apparent disease (Safar, 2000; Schiffrin, 2004). One of the principal modifiable factors that contribute to arterial stiffness is the mean arterial blood pressure (McEniery et

al., 2005; Protogerou et al., 2007; Segers et al., 2009). The mean arterial blood pressure has a greater impact on the small to medium sized muscular arteries, leading to high peripheral vascular resistance (McEniery et al., 2007). As is expected, with an increase in arterial stiffness the compliance of the digital arteries is decreased in patients with essential hypertension (Bochmann et al., 1995).

Although pulse wave velocity as measured by applanation tonometry is considered the gold standard for measurement of arterial stiffness (Laurent et al., 2002).

^{*}Corresponding author. E-mail: dranumeha_bhagat@yahoo.com. Tel: 91-9646121590. Fax: 0172-2608480.

there are several other non invasive methods of measuring the stiffness of the blood vessels. One easy to use and operator independent method is the photoplethysmographic assessment of pulse waveform, which is based on digital volume pulse (DVP) (Millasseau et al., 2000). It has also been suggested that stiffness index (SI) derived from the DVP can be used as a marker for risk stratification in untreated hypertensive patients (Chen et al., 2005). However, the influence of antihypertensive drugs on these arterial stiffness indices by photoplethysmographic method has not yet been studied. Therefore, we conducted a pilot study to explore the relationship between BP and parameters of arterial stiffness on initiating antihypertensive treatment.

MATERIALS AND METHODS

The study was performed at the Department of Physiology, Government Medical College and Hospital, Chandigarh. Newly diagnosed hypertensive patients from medicine outpatient department (OPD) were recruited for the study. Written informed consents were taken from the patients after explaining the nature of the study. Male or female patients between 30 to 40 years were included. Patients with chronic or acute alcohol and/or caffeine intake, smoking, history of cardiovascular disease, diabetes mellitus, asthma, chronic obstructive pulmonary disease (COPD), renal disease or patients on lipid lowering, blood sugar lowering or cardiovascular medications were excluded from the study. Pregnant or lactating females and females using oral contraceptive were also excluded from the study.

The heights of the patients were measured against a wall mounted inelastic measuring tape, with the patient standing erect with feet together. Weight was measured on a weighing scale with the patient in light clothing. The body mass index was calculated using the formula: Weight (kg)/ (Height)² (meters). Blood pressure and arterial stiffness were measured in supine posture in the right arm after the patient had rested for 15 min.

Measurement of blood pressure

Blood pressure (BP) was measured over the brachial artery of the right arm by auscultatory method using a conventional mercury sphygmanometer. Measurements were taken after 15 min of rest in supine posture. Mean arterial pressure (MAP) was calculated using: DBP \pm 1/3 pulse pressure. Pulse pressure was calculated as: systolic pressure – diastolic pressure.

Measurements of arterial stiffness by digital volume pulse analysis

The digital volume pulse (DVP) analysis method is a noninvasive technique of measuring pulse wave reflections, in order to determine the peripheral arterial stiffness (Millasseau et al., 2006). Arterial stiffness, as measured by the DVP analysis method is a validated reproducible technique, with minimal intra observer variations (Chowienczyk et al., 1999; Sollinger et al., 2006). The stiffness index derived from this method has been demonstrated to have a good correlation with pulse wave velocity (PWV) (Sollinger et al., 2006). The sensitivity and specificity of this technique is comparable to the PWV method in the identification of patients with

latent cardiovascular disease (Millasseau et al., 2002; Woodman et al., 2005).

Calculation of the stiffness index (SI) using pulse waveform reflections

The DVP waveform consists of a systolic peak and a second diastolic peak, which is formed by the reflection of the pulse wave from the small arteries in the lower body. The time delay – that is the peak-to-peak time (PPT) between the systolic and diastolic peaks is related to the transit time of pressure waves from the root of the subclavian artery to the apparent site of reflection and back to the subclavian artery. The degree of pulse wave reflection, which is the stiffness index (SI), depends on the impedance of the microvascular bed and the tone of the small-to-medium-sized blood vessels. This path length can be assumed proportional to height (h). Therefore, the SI can be calculated from the formula: SI = h/PPT (Oblouck, 1987).

Arterial stiffness measurement protocol

Arterial stiffness measurement of the healthy volunteers as well as patients was performed in the morning between 9 to 10 am following an overnight fast after refraining from caffeine-containing beverages, alcohol, and smoking in the previous 12 h. The DVP was recorded in the person's right index finger. Volunteers rested for 15 min in supine posture in a temperature-controlled environment before the measurements were taken. All the volunteers were advised to refrain from talking and sleeping when the measurements were being taken. Recorded digital pulse waveforms were used (PCA 2; Micro Medical, UK) to generate indices of arterial stiffness using a standard validated protocol (Millasseau et al., 2006). Each person had at least three measurements (recorded for 30 s) taken 1 min apart, and an average was calculated and used for the analysis. Afterward, antihypertensive drug treatment was started; patients were given either an angiotensin II receptor antagonist or calcium channel blocker or thiazide diuretics. BP and arterial stiffness was measured weekly till three weeks in the manner mentioned earlier.

Statistical analysis

Blood pressure (BP) and arterial stiffness parameters in the hypertensive group were analyzed using analysis of variance (ANOVA) with post hoc analysis.

RESULTS

All results were expressed as mean ± standard deviation (SD). The total number of hypertensive patients was 14. The anthropometric parameters of newly diagnosed hypertensive patients are given in Table 1. Statistical analysis of the data obtained from the hypertensive group before and after treatment was done. On comparing the BP values before treatment and after each week of initiation of treatment for 3 weeks, a highly significant decline in the systolic BP (p< 0.006) and mean BP (0.005) was observed, whereas diastolic BP showed a significant (0.016) decline (Table 2). Multiple

Table 1. Anthropometric characteristics of hypertensive patients.

Characteristic	Hypertensive patients (n = 14; mean ± SD)	
Males	64.3%	
Females	35.7%	
Age	42.43 ± 7.89	
Height	164.71 ± 7.77	
Weight	74.93 ± 5.40	
BMI	27.67 ± 5.74	

Table 2. Pre and post BP treatment and indices of arterial stiffness in the hypertensive patients.

Danamatan	Pre treatment (n = 14)	Post treatment			D -1 -
Parameter		1 st week	2 nd week	3 rd week	- P value
Systolic BP	159.0 ± 19.10	145.56 ± 7.99	136.75 ± 12.42	135.33 ± 9.24	0.006**
Diastolic BP	104.0 ± 14.86	97.56 ± 6.06	89.00 ± 8.21	87.33 ± 3.06	0.016*
PP	55.0 ± 4.31	48.00 ± 6.56	47.75 ± 7.96	48.00 ± 7.21	0.338
Mean BP	122.33 ± 14.95	113.56 ± 6.02	104.92 ± 9.07	103.33 ± 4.81	0.005**
HR	81.29 ± 13.80	77.11 ± 14.11	77.13 ± 13.87	75.33 ± 11.85	0.826
Stiffness index	9.56 ± 1.78	9.25 ± 2.08	8.32 ± 2.15	9.08 ± 1.76	0.641
Reflection index	68.30 ± 9.27	66.25 ± 15.85	65.29 ± 13.19	63.00 ± 15.59	0.924
Peak to peak time	176.70 ± 38.56	187.75 ± 38.87	208.71 ± 45.76	190.33 ± 7.39	0.459

^{*} Significant; ** highly significant.

comparisons on post hoc analysis revealed that the SBP and DBP showed a significant decline (p = 0.011 and 0.027, respectively) at the second visit, which is around two weeks post treatment and mean BP shows a highly significant decrease (p = 0.009) at this time. However, the pulse pressure and heart rate did not change significantly with treatment.

Representative pulse wave tracings as recorded in a hypertensive patient before the beginning antihypertensive treatment (Figure 1) and at the end of three weeks of treatment (Figure 2) are shown. From these tracings also, not much difference in the pulse (and thereby arterial stiffness) appears. Arterial stiffness was measurable in only 10 hypertensive patients. In the other 4 patients, on applying the probe, the message "stiff" was displayed on the screen. This occurs when the large arteries are very stiff so that the direct and reflected wave merges together, making it impossible to distinguish them. No diastolic inflection point can be found and the message "stiff" is displayed.

Furthermore, the pre treatment and post treatment peak to peak time (PPT) at two weeks shows an increase but it is not statistically significant. Other parameters such as SI and RI did not change significantly with treatment for the same duration. Pearson's correlation and p value for different BP and arterial stiffness variables showed that there was a significant positive correlation between RI and SI (0.470) and a significant negative correlation

between RI and PPT (-0.428). SI and PPT were highly significantly negatively correlated (-0.950). Pulse pressure was also significantly correlated with both SI (0.384) and PPT (-0.447), while HR significantly correlated with both SI (0.470) and PPT (-0.428).

DISCUSSION

The relationship between pulse wave velocity (PWV) and blood pressure showed that higher pressure will result in increased PWV as found by Young (1809). For this reason, it would be expected that drug interventions that decrease blood pressure would be associated with a fall in PWV. This has been demonstrated with a range of antihypertensive drugs. However, in these studies, the encounter interval between the doctor and the patient after initiating treatment was > 1 month. In this study, we followed the patients at weekly intervals after initiating antihypertensive treatment in order to determine the relationship between normalization of BP and arterial stiffness. In the hypertensive group, it was seen that by two weeks of treatment the SBP, DBP and mean BP of the patients showed a statistically significant decline and by the third week of treatment the blood pressure showed no further decline. However, the arterial stiffness parameters showed no change in the entire 3 weeks of duration treatment.




Figure 1. Pulse wave form of hypertensive patient before treatment.




Figure 2. Pulse wave form of same patient after the third week of treatment.

The currently recommended encounter interval after initiating treatment in hypertensive patients is 1 month (Jones and Hall, 2004) and this is based largely on expert opinion. However, in a study by Turchin et al. (2010), the difference in time to blood pressure normalization persisted at encounter intervals shorter than the currently recommended. In this study, it was found that in patients with an average encounter interval < = 2 weeks BP normalized after a median of 0.7 months. This was also seen in our study. For an encounter interval of 1 to 2 weeks, the rates of decrease for systolic and diastolic

blood pressures were 43.8 and 13.1 mm Hg/month, respectively (Turchin et al., 2010). From recent research, it is evident that shorter encounter intervals causes faster BP reduction; therefore, if shorter encounter intervals are to be achieved, more creative approaches to patient care are needed (Okie, 2008).

We also observed that although BP normalized in our patient by the end of third week of initiating the treatment, yet there was no alteration in the parameters of arterial stiffness at this time. This indicates that despite mean BP being a major contributor to arterial stiffness, its reduction

after initiation of antihypertensive therapy does not go hand in hand with parameters of arterial stiffness. Probably arterial stiffness takes a longer time to decrease as compared to blood pressure. Physiologically, the stiffness of the large arteries depends on 3 main factors: structural elements within the arterial wall, such as elastin and collagen; distending pressure and vascular smooth muscle tone (McEniery et al., 2006). In single dose or short-term studies, angiotensin-converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), calcium channel blockers (CCBs), selective beta1blockers, beta-blockers with vasodilating properties and some diuretics could improve arterial stiffness (Blacher et al., 2005; Van Bortel et al., 1995). However, it is not clear whether this effect was limited to the decrease in blood pressure, or whether also an effect beyond the effect of blood pressure reduction was present.

After a 6-month treatment period for a similar reduction in blood pressure, the ACEI perindopril showed a more pronounced improvement of carotid artery stiffness than the diuretic amiloride/hydrochlorothiazide (Kool et al., 1995), showing that the de-stiffening potency differs between antihypertensive drugs and suggesting that some may have an effect beyond the effect due to blood pressure decrease. Moreover, a meta-analysis by Ong et al. (2011) revealed that in short-term studies (defined by the authors as a duration <4 weeks), only ACEIs reduced PWV beyond the blood pressure effect, whereas in longterm studies (4 weeks or more), all studied drug classes were effective. Vasodilation may at least in part account for the effect beyond blood pressure reduction of vasoactive drugs such as ACEI, ARB, CCB and betablockers with vasodilating properties. However, the mechanisms by which diuretics and selective beta1blockers would reduce stiffness beyond blood pressure values are unknown. It was also observed that the effect for selective beta1-blockers and diuretics on PWV was comparable to the vasoactive drug classes (Ong et al., 2011). This may suggest that apart from the antihypertensive property of the antihypertensive drug, the sustained unloading of the arteries by blood pressure reduction itself may contribute to structural de-stiffening of arteries within a few months.

Since several mechanisms may be involved in producing reductions in arterial stiffness with a given treatment, assessment of arterial stiffness has to be distinguished between the effects of acute, short-term, or long-term chronic treatments. For example, after acute administration of an antihypertensive drug, improvement of arterial stiffness is principally related to functional or mechanical mechanisms such as reduction of distension pressure, reduction of smooth muscle tone, enhancement of endothelial functions, whereas after long-term chronic treatment, additional mechanisms can be involved; for example changes in the arterial geometry and structure, reduction in degree of fibrosis, increase in elastin/

collagen ratio, remodeling of the arterial wall (Laurent et al., 2006). Experts agree that assessment of arterial stiffness after a long-term treatment period should be preferred because of the underlying patho-physiological mechanisms involved and because acute effects may not predict long term efficacy (Bortela et al., 2011).

Conclusion

From this pilot study, it was concluded that reduction in BP in hypertensive patients as measured clinically by brachial cuff sphygmanometry seemed to be dependent on the encounter interval. The decrease in blood pressure in hypertensive patients occurred earlier within three weeks as compared to the changes in arterial stiffness, which did not occur even till three weeks of initiating the treatment.

REFERENCES

- Blacher J, Protogerou AD, Safar ME (2005). Large artery stiffness and antihypertensive agents. Curr. Pharm. Des. 11:3317–3326.
- Bochmann RP, Reuter U, List A, Grundig M, Sinz V (1995). Compliance of the digital artery is decreased in patients with essential hypertension. J. Hum. Hypertens. 9(8):627-31.
- Bortela LMV, Backera TD, Buyzerea MD (2011). How to treat arterial stiffness beyond blood pressure lowering. J. Hypertens. 29:1051–1053.
- Chen JY, Tsai WC, Lin CC, Huang YY, Hsu CH, Liu PY, Chen JH (2005). Stiffness index derived from digital volume pulse as a marker of target organ damage in untreated hypertension. Blood Press. 14:233–237.
- Chowienczyk PJ, Kelly RP, MacCallum H, Millasseau SC, Andersson TL, Gosling RG (1999). Photoplethysmographic assessment of pulse wave reflection: blunted response to endothelium-dependent beta2-adrenergic vasodilation in type II diabetes mellitus. J. Am. Coll. Cardiol. 34:2007-2014.
- Jones DW, Hall JE (2004). Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension 43:1–3.
- Kool MJ, Lustermans FA, Breed JG, Struijker-Boudier HA, Hoeks AP, Reneman RS, Van Bortel LM (1995). The influence of perindopril and diuretic combination amiloride/ hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J. Hypertens. 13:839–848.
- Laurent S, Cockcroft J, Bortel LV, Boutouyrie P, Giannattasio C, Hayoz D, Pannier B, Vlachopoulos C, Wilkinson I, Struijker-Boudier H (2006). Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur. H. J. 27:2588-2605.
- Laurent S, Kingwell B, Bank A (2002). Clinical applications of arterial stiffness: therapeutics and pharmacology. Am. J. Hypertens. 15:453-458.
- McEniery CM, Wallace S, Mackenzie IS, McDonnell B, Yasmin, Newby DE, Cockcroft JR, Wilkinson IB (2006). Endothelial Function Is Associated With Pulse Pressure, Pulse Wave Velocity, and Augmentation Index in Healthy Humans. Hypertension 48:602-608.
- McEniery CM, Wilkinson IB, Avolio AP (2007). Age, hypertension and arterial function. Clin. Exp. Pharmacol. Physiol. 34:665-671.
- McEniery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR (2005). Normal vascular aging: differential effects on wave reflection and pulse wave velocity. The Anglo-Cardiff Collaborative Trial

- (ACCT). J. Am. Coll. Cardiol. 46:1753-1760.
- Millasseau SC, Guigui FG, Kelly RP, Prasad K, Cockcroft JR, Ritter JM, Chowienczyk PJ (2000). Noninvasive Assessment of the Digital Volume Pulse: Comparison with the Peripheral Pressure Pulse. Hypertension 36:952-956.
- Millasseau SC, Kelly RP, Ritter JM, Chowienczyk PJ (2002). Determination of age-related increases in large artery stiffness by digital pulse contour analysis. Clin. Sci. (Lond) 103:s 371–377.
- Millasseau SC, Ritter JM, Takazawa K, Chowienczyk PJ (2006). Contour analysis of the photoplethysmographic pulse measured at the finger. J. Hypertens. 24:1449–1456.
- Oblouck G (1987). Haemodynamic monitoring. Philadelphia: WB Saunders: p. 56.
- Okie S (2008). Innovation in primary care—staying one step ahead of burnout. N. Engl. J. Med. 359:2305–2309.
- Ong KT, Delermed S, Pannierb B, Safarc M, Benetos A, Laurent S, Boutouyrie P (2011). Aortic stiffness is reduced beyond blood pressure lowering by short-term and long-term antihypertensive treatment: a meta-analysis of individual data in 294 patients. J. Hypertens. 29:1034-1042.
- Protogerou AD, Blacher J, Mavrikakis M, Lekakis J, Safar ME (2007). Increased pulse pressure amplification in treated hypertensive subjects with metabolic syndrome. Am. J. Hypertens. 20:127-133.
- Safar ME (2000). Pulse pressure, arterial stiffness, and cardiovascular risk. Curr. Opin. Cardiol. 15:258–263.
- Schiffrin EL (2004). Vascular stiffening and arterial compliance: Implications for systolic blood pressure. Am. J. Hypertens. 17:39-48S.

- Segers P, Mahieu D, Kips J, Rietzschel ER, De Buyzere ML, De Bacquer D, Bekaert S, De Backer G, Gillebert TC, Verdonck P, Van Bortel LM, on behalf of the Asklepios investigators (2009). Amplification of the pressure pulse in the upper limb in healthy, middle-aged men and women. Hypertension 54:414-420.
- Sollinger D, Mohaupt MG, Wilhelm A, Uehlinger D, Frey FJ, Eisenberger U (2006). Arterial stiffness assessed by digital volume pulse correlates with comorbidity in patients with ESRD. Am. J. Kidney Dis. 48:456-463.
- Turchin A, Goldberg SI, Shubina M, Einbinder JS, Conlin PR (2010). Encounter frequency and blood pressure in hypertensive patients with diabetes mellitus and hypertension. 56:68-74.
- Van Bortel LM, Kool MJ, Struijker-Boudier HA (1995). Effects of antihypertensive agents on local arterial distensibility and compliance. Hypertension 26:531-534.
- Woodman RJ, Kingwell BA, Beilin LJ, Hamilton SE, Dart AM, Watts GF (2005). Am J. Assessment of central and peripheral arterial stiffness: studies indicating the need to use a combination of techniques. Hypertension 18:249-260.
- Young T (1809). The Croonian lecture on the functions of the heart and arteries. Philos. Trans. R. Soc. Lond. 24:1-31.

Full Length Research Paper

Investigation of influence of inside out transobturator vaginal tape (TVT-O) procedure on objective, subjective cure rates and different quality of life tests in stress urinary incontinence treatment

Murat BOZKURT1* and A. Ender YUMRU2

¹Universal Malatya Hastanesi Turgut Özal Bulvarı Ankara Asfaltı 6 km No: 219 44000 Malatya, Turkey. ²Taksim Education and Research Hospital, İstanbul, Turkey.

Accepted 28 August, 2012

This study was aimed at Investigating the influence of the transobturator tape (TOT) procedure used in surgical treatment of stress urinary incontinence on objective and subjective cure rates, as well as quality of life. A total of 156 patients who were diagnosed as stress incontinence and mixed incontinence with stress predominancy, underwent a TOT operation under spinal anesthesia by one surgeon or two surgeons of the team. Transobturator vaginal tape (TVT)-obturator inside out material (TVT-O® (Gynecare) was used in the operation. All patients underwent preoperative and postoperative urodynamic tests and pad tests, and the results were compared. The objective and subjective cure rates were investigated in mean of 30.3 months of follow-up. The objective cure was evaluated with negative cough test and less than 8 g 24-h pad test, while the subjective cure was evaluated with Patient Global Impression of Improvement (PGI). All patients were given IIQ-7, UDI-6, UISS and VAS tests at least once and the influence of the operation upon quality of life was investigated. According to the result obtained, the mean follow up time was 30.3 ± 7.4 months (range 17 - 42). The objective cure rate was found to be 84.6% (132 patients), the subjective cure rate was found to be 89% (139 patients) and the failure rate was found to be 10.8% (17 patients). Preoperative and postoperative pad test results of the patients were found to be statistically significant (38 ± 22.3 vs. 1±2.6 p<005). Among urodynamics and symptoms evaluated pre- and postoperatively, a statistically significant difference was detected between the Q tip test (43.60 vs. 20.8), leaks over 24 h (4 vs. 0), daytime frequency/nocturia (0.95 vs. 0.58) and maximum urethral closure pressure (57.3 vs. 35) (p<0.05). The preoperative and postoperative incontinence impact questionnaire-short form (IIQ-7) (11 vs. 0.6), urogenital distress inventory-short form (UDI-6) (14 vs. 7), urinary incontinence severity score (UISS) (11 vs. 2.8) and the visual analogue scale (VAS) (68 vs. 8) quality of life tests showed a significant difference (p<0.05). Summarily, the objective and subjective cure rates of the TOT procedure in the surgical treatment of female stress incontinence were quite high, thus it is an effective technique. The influence of this operation on quality of life scores evaluated with various parameters is satisfying.

Key words: Transobturator tape (TOT), objective and subjective cure rates, urinary incontinence.

INTRODUCTION

Since the first reports from the Ulmsten group, Tension-

free Vaginal Tape (TVT®, Gynecare), the first polypropylene mid-urethral sling put on the market, has become one of the most commonly performed procedures worldwide due to the ease of performance and high success rates. And to date, several hundred thousand TVT procedures have been performed.

^{*}Corresponding author. E-mail: jindrmb@yahoo.com. Tel: 904222382828/1546. Fax: 904222382600.

Table 1. Preoperative and p	ostoperative urod	lynamic evalu	ations of patients.
------------------------------------	-------------------	---------------	---------------------

Urodynamic evaluation	Preoperatif	Postoperatif
Q-tip test (°)	43.60 ± 20.4	20.8 ± 14.9*
First desire to void (ml)	185 ± 78.3	209.8 ± 45.2
Maximum detrusor pressure (cm H2O)	17.48 ± 6.03	20.2 ± 3.6
ALPP (cm H ₂ O)	80.80 ± 25.57	75.1 ± 19.63
Cystometric capacity (ml)	496.80 ± 65.63	488 ± 75.8
Compliance (ml/cm H ₂ O)	58.61 ± 20.83	60.13 ± 25.72
Residual urine (ml)	13.2 ± 8.9	14.8 ± 18.5
Maximum urethral closure pressure	57.3 ± 9.4	$35 \pm 7.3^*$
Leaks over 24 hours	(1 - 6)	0*
Peak flow	25.8 ± 7.1	28.4 ± 6.4
Daytime frequency/nocturia	0.95 ± 1.46	0.58 ± 0.62*

ALPP: Abdominal leak- point pressure; *statistically significant difference p<00.5.

Moreover, several devices have been introduced onto the market to ensure that mid-urethral sling procedures are now even less invasive, including the Suprapubic Arc (SPARC™ Sling System [American Medical Systems UK Ltd, Brentford, UK]) sling, the intravaginal (IVS) sling, transobturator slings, pre-pubic TVT and, more recently, the so-called mini-slings (the TVT-Secur and Mini-Arc slings).

The choice of the best surgical approach for each patient with stress urinary incontinence depends on several issues, including the patient's age, expectations and co-morbidity, previous reconstructive procedures, symptom severity. risk of intraoperative postoperative complications, recovery time and long-term success rate. The transobturator tape (TOT) procedure has been recently developed as a new minimally invasive sling procedure. It is thought to have the benefits of easy performance and decreased risk of bladder and visceral injury. Two types of TOT have been performed, the inside-out (TVT-O) and the outside-in transobturator tape (TOT) approaches with the choice of the surgical approach predominantly driven by the surgeon's preference. This study was aimed at Investigating of the influence of the transobturator tape (TOT) procedure used in surgical treatment of stress urinary incontinence on objective and subjective cure rates, as well as quality of life.

MATERIALS AND METHODS

A total of 156 patients with stress incontinence who were admitted to the Gynecology and Obstetrics Clinics of Taksim Research and Training Hospital and Şırnak Idil State Hospital between May 2005 and January 2010 were included in this retrospective study. A detailed anamnesis, including duration and severity of stress incontinence was obtained from the patients. All patients had experienced these symptoms for more than 4 years. Symptoms were found to be grade 2 (grade 1-3) according to Ingelman-Sundberg scale. All patients underwent vaginal examination and transvaginal ultrasonography. All menopausal patients were

administered a local estrogen treatment (estriol vaginal cream, Assos pharmaceuticals). For urogynecologic evaluation, a stress test was applied in standing and lying positions after the urinary bladder had been expanded with 300 ml isotonic solution. In addition, 24 and 48 h pad follow ups were performed.

Urodynamic tests such as cystometry were used in all patients for the discrimination of stress and urge urinary incontinence. Urodynamic evaluation as shown in Table 1, was done using Laborie and Medical Measurement System (MMS) urodynamic devices. A sterile 8 French dual channel cystometry catheter was placed into the urethra and a rectal catheter with 5 ml balloon was placed into the rectum when the patient was in lithotomy position. Cystometric assessment was done after residual urine measurement had been performed. The urinary bladder was filled with saline solution at room temperature at the rate of 50 ml/min and the patient was asked to cough after each 100 ml filling. Urinary incontinence occurring in this time was detected and the diagnosis of stress incontinence was made. Urodynamic diagnosis of detrusor instability (urge incontinence) was made upon detection of an elevation 15 cm H₂O or above in basal detrusor pressure in cystometry. All patients were administered 2 g parenteral cefazolin preoperatively for antibacterial prophylaxis. While the patients who would undergo only TOT did not have vaginal lavage applied, this procedure was applied preoperatively to the patients who would undergo additional surgery (cystocele). The TOT procedure was performed as described by Leval. Patients who were applied general or local anesthesia, who underwent vaginal surgery except anterior repair, who desired to have a baby, and who had severe systemic diseases or mixed urinary incontinence with urge incontinence predominancy were excluded from the study. All patients were administered with regional (spinal) anesthesia.

Cystoscopy was performed to evaluate the bladder and urethra after the procedure. Patients who would undergo cystocele operation had the additional intervention performed after the prolene band had been placed. Afterwards, a stress test was applied, the band level was adjusted and the operation was terminated. The duration of TOT, cystoscopy and any additional operations, if performed, were recorded. All patients were monitored with the Foley catheter for bladder drainage for 24 h. The catheter was removed if residual volume was below 100 ml at the end of 24 h and intermittent catheterization was performed if postvoiding residual volume was above 100 ml. Similar protocols were applied for pre, peri and post-operative assessments in both clinics. All surgical procedures were performed by one or two members of the surgical team. Postoperative controls were done at 2, 6, 12, 24 and 48 months. The objective cure was evaluated with a negative

cough test and a 24-h pad test's being less than 8 g; the subjective cure was evaluated with Patient Global Impression of Improvement (PGI).

The influence of TOT on quality of life of the patients was evaluated with the Incontinence Impact Questionnaire-Short Form (IIQ-7), urogenital distress inventory-short form (UDI-6), urinary incontinence severity score (UISS) and the visual analogue scale (VAS), tested pre- and postoperatively. The last studied objective, subjective cure rates and quality of life scores were used in the study. Assessments done within the first postoperative 2 months could be applied to all patients. So those first assessments were taken essentially in the patients who were last to be followed up on. Statistical analyses were done using the Statistical Package for Social Science (SPSS Inc, Chicago, Illonois, USA) 15.0 program. Constant data were given as mean ± standard deviation (SD) and analyzed with the Wilcoxon's signed rank test for statistical significance. Categorical data were given as numerical values and in percentages. A p level <0.05 was accepted as statistically significant.

RESULTS

The mean duration of follow up was 30.3 ± 7.4 (range 17 - 42) years. The mean age of the patients was found as 48.43 ± 6.24 years (range 42 - 68). The mean parity of the patients was 5.24 ± 2.86 (min 2 - max 13) and the mean body mass index was found to be 23.7 ± 4.8 (Table 2).

DISCUSSION

Urinary incontinence (UI) is a prevalent condition that affects approximately 27% of women worldwide, with farreaching physical, psychological, social, and economic implications. Incontinence has been found to reduce health-related quality of life to roughly the same degree as chronic conditions such as depression and Type I diabetes (Milsom, 2009; Stach-Lempinen et al., 2004). Personal consequences include restriction of physical and social activity, self-imposed social isolation and sexual dysfunction (Oh et al., 2008). The transobturator tape (TOT) procedure has recently been developed as a new minimally invasive sling procedure. It is thought to have the benefits of easy performance and decreased risk of bladder and visceral injury (Ward and Hilton, 2004). Spinosa and Dubuis (2005) followed up 117 patients who underwent TOT for 16.3 months, and the complete and partial subjective cure rates were found as 92.3% (n:108) and 4.2% (n:5), respectively. Overall, four patients stated that their condition did not change. In another study that 120 patients were followed up for one year, 80% patients reported that they were completely dry and 12% reported that they had recovered almost totally. Globally, 78% patients reported that their incontinence improved well during daily activities, exertion and sexual intercourse (Roumeguère et al., 2005). Waltregny et al. (2006) found complete cure rate of 91% after TVT-O procedure on one-year follow up. A significant improvement was also detected in the quality

Table 2. Diagnosis and distribution of the patients.

Data	Total number of patient
Stress Incontinence	100 (64.1%)
Mixed Incontinence	56 (35.9%)
Previous incontinence surgery	20 (12.8%)

The mean operative time was found to be 13.8±5.16 min in patients who underwent only TOT and TOT-anterior repair.

of life and severity of incontinence in most patients. In another study with a mean of 4 months follow up, the objective and subjective cure rates were found to be 92 and 97%, respectively. An improvement was observed in the quality of life of 96% patients (Cindolo et al., 2004). In an additional study including 94 patients with a mean of 12.8 months of follow up, the cure rate was found to be 95% (Mellier et al., 2004).

In our study including 156 patients with a mean follow up time of 30.3 months, the objective and subjective cure rates were found to be 84 and 89%, respectively (Table 3). The objective and subjective cure rates seem lower than the aforementioned studies. We considered that this is due to the follow-up period. Cure rates decline as the duration of follow up increases. In parallel with this, Giberti et al. (2007) reported an 80% cure rate with 2 years of follow up, while Waltregny et al. (2008) reported an 88% cure rate with a 3 year follow up period. Clues were obtained about mid-term outcomes of this procedure with an 82.4% cure rate with 4 years of follow up with a group of 74 patients who underwent TVT-O (Liapis et al., 2010). The fact that 35.9% of the patients in our study group had mix incontinence without detrusor overactivity may have affected success rates. Holmgren et al. (2005) detected low cure rates in patients with mixed urinary incontinence. The success rate of 60% in 4 years was seen to decline to 30% in 4-8 years. However, the success rate of pure stress urinary incontinence is 82% in this study (Holmgren et al., 2005). Paick et al. (2007) did not detect a statistically significant difference between pure and mixed stress urinary incontinence in terms of cure rates. In a review, it was stated that mixed urinary incontinence could be successfully treated with mid-urethral slings; however, persistent urge symptoms could severely affect the quality of life for the patients (Fong and Nitti, 2010). Similar to our study, in a study also including the effect of the operation done after TOT procedures, a significant difference was detected between preoperative and postoperative assessment scores. In this study, a significant improvement was seen in UISS, DIS, VAS, IIQ-7, UDI-6 scores tested preoperatively and 2 months postoperatively (Table 4). In our study, all quality of life tests except DIS were used and similar results were obtained (Laurikainen et al., 2007). Shalom et al. (2011) stated that mid-urethral sling placement via suprapubic route provided better quality of life scores compared to transvaginal route in female

Table 3. Objective, subjective cure rates and failure in patients who underwent TOT.

Data	Total number of patient (%)	
Objective cure rate	132 (84.6)	
Subjective cure rate	139 (89.1)	
Failure	17 (10.8)	

Preoperative and postoperative pad test results of the patients were found to be statistically significant (38 \pm 22.3 vs. 1 \pm 2.6 g; p=0.021 p<00.5).

Table 4. Preoperative and postoperative quality of life tests of the patients.

Quality of life test	Preoperative	Postoperative
UISS	11 ± 4	2.8 ± 1*
VAS	68 ± 24	8 ± 2*
IIQ-7	16 ± 4	$6 \pm 3*$
UDI-6	14 ± 3	7 ± 2*

UISS: Urinary incontinence severity score; VAS: visual analogue scale; IIQ-7: incontinence impact questionnaire-short form; UDI-6: urogenital distress inventory- short form. *Statistically significant difference P<00.5.

stress urinary incontinence. While there was not a difference between preoperative UDI-6 scores in both groups, lower UDI-6 scores were found in postoperative suprapubic group.

In our study, when the high length of follow-up periods and the existence of mix incontinence and recurrend incontinence cases are considered, the objective and subjective cure ratios were found to be high compared to similar studies in the literature. Also, in all life quality scores evaluated by 4 different tests, a statistically significant improvement was seen after TOT operation.

Conclusion

The objective and subjective cure rates of TOT procedure in surgical treatment of female stress incontinence are quite high, thus it is an effective technique. In addition, the influence of this operation on quality of life scores evaluated within the various parameters is also satisfying.

REFERENCES

Cindolo L, Salzano L, Rota G, Bellini S, D'Afiero A (2004). Tension-free transobturator approach for female stress urinary incontinence. Minerva Urol. Nefrol. 56:89-98.

- Fong ED, Nitti VW (2010). Mid- urethral synthetic slings for female stress urinary incontinence. BJU Int. 106:596-608.
- Giberti C, Gallo F, Cortese P, Schenone M (2007). Transobturator tape for treatment of female stress urinary incontinence: objective and subjective results after a mean follow-up of two years. Urology 69:703-707.
- Holmgren C, Nilsson S, Lanner L, Hellberg D (2005). Long-term results with tension-free vaginal tape on mixed and stress urinary incontinence. Obstet. Gynecol. 106:38-43.
- Laurikainen E, Valpas A, Kivelä A, Kalliola T, Rinne K, Takala T, Nilsson CG (2007). Retropubic compared with transobturator tape placement in treatment of urinary incontinence: a randomized controlled trial. Obstet Gynecol. 109:4-11.
- Liapis A, Bakas P, Creatsas G (2010). Efficacy of inside-out transobturator vaginal tape (TVTO) at 4 years follow up. Eur. J. Obstet. Gynecol. Reprod. Biol. 148:199-201.
- Mellier G, Benayed B, Bretones S, Pasquier JC (2004). Suburethral tape via the obturator route: is the TOT a simplification of the TVT? Int. Urogynecol. J. Pelvic Floor Dysfunct. 15:227-232.
- Milsom I (2009). Lower urinary tract symptoms in women. Curr Opin Urol. 19:337-341.
- Oh SJ, Ku J, Choo MS, Yun J, Kim D, Park WH (2008). Health-related quality of life and sexual function in women with stress urinary incontinence and overactive bladder. Int. J. Urol. 15:62-7.
- Paick JS, Cho MC, Oh SJ, Kim SW, Ku JH (2007). Factors influencing the outcome of mid urethral sling procedures for female urinary incontinence. J. Urol. 178:985- 9.
- Roumeguère T, Quackels T, Bollens R, de Groote A, Zlotta A, Bossche MV, Schulman C (2005). Trans-obturator vaginal tape (TOT) for female stress incontinence: one year follow-up in 120 patients. Eur. Urol. 48:805-809.
- Shalom DF, Klapper AS, Lin SN, Winkler HA (2011). Comparison of quality-of-life changes in patients with stress urinary incontinence after midurethral sling placement. Int. J. Gynaecol. 114:137-40.
- Spinosa JP, Dubuis PY (2005). Suburethral sling inserted by the transobturator route in the treatment of female stress urinary incontinence: preliminary results in 117 cases. Eur. J. Obstet. Gynecol. Reprod. Biol. 123:212-217.
- Stach-Lempinen B, Sintonen H, Kujansuu E (2004). The relationship between clinical parameters and health related quality of life as measured by the 15D in incontinent women before and after treatment. Acta Obst. Gynecol. Scand. 83:983-988.
- Waltregny D, Gaspar Y, Reul O, Hamida W, Bonnet P, de Leval J (2008). TVT-O for the treatment of female stress urinary incontinence: results of a prospective study after a 3-year minimum follow-up. Eur. Urol. 53:401-408.
- Waltregny D, Reul O, Mathantu B, Gaspar Y, Bonnet P, de Leval J (2006). Inside out transobturator vaginal tape for the treatment of female stress urinary incontinence: interim results of a prospective study after a 1-year minimum follow up. J. Urol. 175:2191-215.
- Ward KL, Hilton P (2004). A prospective multicenter randomized trial of tension-free vaginal tape and colposuspension for primary urodynamic stress incontinence: a two year follow-up. Am. J. Obstet. Gynecol. 190:324-331.

UPCOMING CONFERENCES

<u>Hawaii Heart 2013: Echocardiography & Multimodality Imaging, Case Based Clinical Decision</u>
Making, Kauai, USA, 4 Feb 2013



14th Annual Clinical Trial Supply Europe, Berlin, Germany, 26 Feb 2013



9th International Conference on Clinical Ethics Consultation, Munich, Germany, 14 Mar 2013



Conferences and Advert

March 2013

11th International Conference of Chemistry & its Role in Development, ElSheikh, Egypt, 11 Mar 2013

April 2013

23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 27 Apr 2013

3rd International Conference on Clinical and Experimental Cardiology, Chicago, USA, 15 Apr 2013

Journal of Clinical Medicine and Research

Related Journals Published by Academic Journals

- Journal of Metabolomics and Systems Biology
- Journal of Neuroscience and Behavioral Health
- Journal of Physiology and Pathophysiology
- Journal of Public Health and Epidemiology
- Medical Case Studies
- Medical Practice and Reviews
- Journal of General and Molecular Virology
- Research in Pharmaceutical Biotechnology

academicJournals